Prosecution Insights
Last updated: May 29, 2026
Application No. 18/256,114

BENZOPYRAZOLE INHIBITORS OF SARM1

Non-Final OA §102§112
Filed
Jun 06, 2023
Priority
Dec 08, 2020 — provisional 63/122,682 +1 more
Examiner
MCDOWELL, BRIAN E
Art Unit
1624
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Disarm Therapeutics Inc.
OA Round
2 (Non-Final)
74%
Grant Probability
Favorable
2-3
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 74% — above average
74%
Career Allowance Rate
825 granted / 1111 resolved
+14.3% vs TC avg
Strong +31% interview lift
Without
With
+30.6%
Interview Lift
resolved cases with interview
Typical timeline
2y 2m
Avg Prosecution
47 currently pending
Career history
1169
Total Applications
across all art units

Statute-Specific Performance

§101
0.3%
-39.7% vs TC avg
§103
23.5%
-16.5% vs TC avg
§102
19.1%
-20.9% vs TC avg
§112
51.1%
+11.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1111 resolved cases

Office Action

§102 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Status of Claims Claims 1-3 and 5-16 are pending in the instant application. Claims 9-11 and 14-16 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. An action on the merits of claims 1-3, 5-8, 12, and 13 is contained herein. The elected species was found free of the art and the search extended to cover species of a proper Markush grouping wherein A = phenyl, L is a C1-4 aliphatic chain, and R1,2 = heterocycle. Any species outside the scope of the latter have not been searched and patentability of claims embracing these outside species have not been fully determined (see objected to claims with the exception of claim 12). Previous Objections/Rejections Any rejections or objections stated of record in the office action mailed on 1/29/2026 that are not explicitly addressed herein below, are hereby withdrawn in light of applicant's arguments and/or amendments filed 4/22/2026. New Rejections Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 2-3 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention. Claims 2-3 recite chemical formulas “I-a” and “I-a-i”. However the chemical structures of these formulas are not shown in the claims. Thus the claims are indefinite. Correction is required. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention. Claims 1, 8, and 13 are rejected under 35 U.S.C. 102(a)(1) as being anticipated over WO 2016/097870. WO 2016/097870 teach the following compounds and compositions thereof starting at page 67 of the disclosure (see claim 41, page 83 for compositions): PNG media_image1.png 114 284 media_image1.png Greyscale PNG media_image2.png 132 212 media_image2.png Greyscale wherein the compounds have the limitation A = phenyl, n = 0, R1 = dimethyl substituted heteroaryl, L = methylene, and R2 = optionally substituted heterocycle. Thus the claims are anticipated. Applicants are to be aware of other species in this document which may anticipate the claims. Conclusion Claims 1-3, 8, and 13 are rejected. Claims 5-7 are objected to for dependency on a rejected claim but have not been determined for full patentability as explained above due to possessing limitations outside of what was searched above and found art of record. Claim 12 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRIAN E MCDOWELL whose telephone number is (571)270-5755. The examiner can normally be reached on 8:30-6 MF. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Murray can be reached at 571-272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BRIAN E MCDOWELL/Primary Examiner, Art Unit 1624
Read full office action

Prosecution Timeline

Jun 06, 2023
Application Filed
Jan 29, 2026
Non-Final Rejection mailed — §102, §112
Apr 22, 2026
Response Filed
May 22, 2026
Final Rejection mailed — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12636371
Chemically Coupled Transporter for Low-Hydrophobicity Bioactive Drugs into the Central Nervous System
2y 2m to grant Granted May 26, 2026
Patent 12617782
PYRIDAZINONES AS PARP7 INHIBITORS
2y 11m to grant Granted May 05, 2026
Patent 12617774
SUBSTITUTED INDOLE COMPOUNDS AND METHODS OF USE THEREOF
11m to grant Granted May 05, 2026
Patent 12612381
CRYSTALLINE FORMS OF N-(4-(4-(CYCLOPROPYLMETHYL)PIPERAZINE-1-CARBONYL)PHENYL)QUINOLINE-8-SULFONAMIDE
4y 3m to grant Granted Apr 28, 2026
Patent 12606556
TYK-2 INHIBITOR
3y 8m to grant Granted Apr 21, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

2-3
Expected OA Rounds
74%
Grant Probability
99%
With Interview (+30.6%)
2y 2m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1111 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month